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VARS1 mutations associated with neurodevelopmental disorder are located on a short
amino acid stretch of the anticodon-binding domain
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Abstract: Majority of 37 human aminoacyl tRNA synthetases have been incriminated in diverse, mostly recessive, genetic diseases. In
accordance with this, we uncovered a novel homozygous valyl-tRNA synthetase 1 (VARS1) gene variant, leading to p.T1068M mutation.
As in the previously reported VARS1 mutations, the affected individual harboring p.T1068M was experiencing a neurodevelopmental
disorder with intractable seizures, psychomotor retardation, and microcephaly. To link this phenotypic outcome with the observed
genotype, we structurally modeled human VARS1 and interpreted p.T1068M within the spatial distribution of previously reported
VARS1 variants. As a result, we uncovered that p.T1068M is clustered with three other pathogenic mutations in a 15 amino acid long
stretch of the VARS1 anticodon-binding domain. While forming a helix-turn-helix motif within the anticodon-binding domain, this
stretch harbors one-fourth of the reported VARS1 mutations. Here, we propose that these clustered mutations can destabilize the
interactions between the anticodon-binding and the tRNA synthetase domains and thus hindering the optimal enzymatic activity of
VARS1. We expect that the depiction of this mutation cluster will pave the way for the development of drugs, capable of alleviating the
functional impact of these mutations.
Key words: VARS1, whole exome sequencing, protein stability, structural modeling, mutation modeling, psychomotor retardation

1. Introduction
Aminoacyl tRNA synthetases (ARSs) are ancient
housekeeping genes. ARSs are ubiquitously expressed
in all cells to catalyze the esterification of amino acids
with their specific tRNA. Such specific tRNAs carry an
appropriate anticodon sequence, which will be translated
to messenger RNAs for the high fidelity production
of proteins (Schimmel, 2018). There are 37 different
human ARSs encoded by different genes. Majority of
these ARSs are located either in the cytoplasm or in
the mitochondria (except three functioning in both
compartments) (Antonellis and Green, 2008). As reviewed
in 2017, 31 ARS genes have been incriminated in different,
mostly recessive, genetic diseases (Meyer-Schuman and
Antonellis, 2017). Most of these profiled mutations show
loss-of-function effects, leading to serious problems
during protein translation. There are also examples

where the ARS mutations can be tolerated, showing that
such disease-causing missense variants may retain some
residual activity (Meyer-Schuman and Antonellis, 2017).
Among the ARS genes, two homozygous Valine ARS
(VARS1) variants were first identified in two individuals
affected by neurological disorders (Karaca et al., 2015).
Both individuals had severe developmental delay,
microcephaly, seizures, and cortical atrophy. Expanding
on this study, we screened a small set of Turkish families
composed of consanguineous couples with children
having neurological disorders. Through whole exome
sequencing (WES), we detected a novel homozygous
VARS1 variant i.e. p.T1068M, in an affected individual
who was experiencing microcephaly, developmental delay,
and drug-resistant seizures. The p.T1068M, VARS1 variant
is located in close vicinity of the pathogenic p.R1058Q
(Karaca et al., 2015), as well pathogenic p.M1064I and
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p.F1072L mutations (Okur et al., 2018; Stephen et al.,
2018). All these mutations are all localized in a helix-turnhelix motif of the anticodon-binding domain, suggesting
a functionally critical region for this enzyme. To interpret
the effect of these mutations on the function of VARS1,
we structurally modeled human p.R1058Q; p.M1064I;
p.T1068M; p.F1072L VARS1 bound to their tRNA by using
Thermus thermophilus VARS as a template. As a result, we
observed that these clustered mutations could lead to the
destabilization of the interactions between anticodonbinding and catalytic tRNA synthetase domains, thus to a
potential loss-of-function.
2. Methods
2.1. Ethics statement
The ethics committee approval for this study was granted by
the Dokuz Eylül University Ethics Committee (document
id: 446-SBKAEK). We also took a written consent from the
parents of the affected individual.
2.2. Next generation whole exome sequencing
The genomic DNA isolation from blood was performed
with Invitrogen PureLink Genomic DNA kit (Cat #:
K1820-01) according to the manufacturer’s protocol.
Isolated DNA of the proband, one sister, mother, and
father were randomly chopped into smaller fragments
by sonication, then electrophoresed on 1% agarose
gel. Fragments with 400–500 bp length were selected.
The fragments corresponding to protein-coding exons
were purified with Agilent SureSelect kit. Libraries for
Illumina platform were prepared, the optimized barcode
sequences were added. By this, four to five libraries could
be sequenced in one sequencing lane. The sequencing was
carried out in Illumina HiSeq2500 platform at TÜBİTAK
Marmara Research Center DNA Services Facility (Gebze,
Turkey) where the relevant FASTQ files were obtained.
Sequencing reads were aligned to GRCh37/hg19 human
reference genome with BWA (v.0.7.16a) (Li and Durbin,
2010). The variant calling step was performed with
HaplotypeCaller of Genome Analysis Tool Kit (GATK;
v.3.6.0) (DePristo et al., 2011). SnpEff package (v.4.1) was
used for variant annotation (Cingolani et al., 2012). The
variants with low depth of coverage (<7) and quality score
(<30) were not considered for the downstream analysis.
For the filtering, the variants that were homozygous
in the proband and heterozygous in each parent were
considered. Homozygous variants in the unaffected sibling
were removed. The minor allele frequency (MAF) was
chosen to be <0.005 in the global allele frequency of the
Genome Aggregation Database (gnomAD; http://gnomad.
broadinstitute.org/). The remaining variants were then
prioritized according to their mammalian conservation
(GERP and PhyloP), predicted deleteriousness (SIFT,
PolyPhen2 and MutationTaster) and putative impact
(high, moderate, or low).

2.3. Sanger validation and segregation analysis by
restriction enzyme analysis
The genomic location of candidate variant detected by
the next generation WES was amplified by polymerase
chain reaction (PCR) via appropriate primers for Sanger
validation and restriction digestion. For confirming the
WES results, primers covering the mutation site were
designed to amplify 488 bp DNA fragment by PCR using
high fidelity Phusion polymerase. The amplified fragment
of proband was sent to Sanger Sequencing (TRiOGEN)
for forward and reverse reading. The sequences were
investigated with FinchTV 1.4.0 program. The variant
site is a recognition site for the Tsp45I digestion enzyme
(New England Biolabs ref no: R0583S), which stalled the
digestion of the proband DNA. Therefore, the parental and
other two sisters’ DNA restriction digestion was used for
confirmation. For the restriction reaction, the conditions
were set with 10× CutSmart buffer (New England Biolabs
#B7204S), in 20 mL, which was incubated at 65 °C 1 h
according to manufacturer’s directions. One percent
agarose gel electrophoresis was performed to detect the
segregated DNA bands.
2.4. Structural modeling of p.R1058Q, p.M1064I,
p.T1068M, and p.F1072L VARS1
The best structural template to model human VARS1
was the Thermus thermophilus valyl-tRNA Synthetase
(pdb id: 1IVS (Fukai et al., 2003), with 52.9% of sequence
similarity. By using 1IVS as the template, VARS1 structural
model was constructed with MODELLER (Webb and Sali,
2014). As 1IVS did not contain any structural information
on 879-916 amino acid range, this region was excluded
during model building. Here, we used standard homology
modeling, as AlphaFold2 could not produce a model
compatible with RNA binding (Supplementary Figure 1A).
MODELLER was run through the MPI Bioinformatics
Toolkit web service (https://toolkit.tuebingen.mpg.de/#/)
(Alva et al., 2016). Modeled human VARS1 was aligned
on top of 1IVS with the “align” command of PyMOL
(Schrödinger LLC, 2015). The Thermus thermophilus
tRNA-Val was isolated together with human VARS1
model. The human VARS1-tRNA complex was refined
with HADDOCK 2.2 (Van Zundert et al., 2016). p.R1058Q,
p.M1064I, p.T1068M, p.F1072L VARS1 mutations
were imposed one at a time by using the HADDOCK
as described at https://www.bonvinlab.org/software/
haddock2.4/faq/#what-about-point-mutations.
2.5. Measuring the impact of the mutation cluster on
VARS1 stability
The structural impact of the clustered mutations
(p.R1058Q, p.M1064I, p.T1068M, p.F1072L) was assessed
based on their interdomain contact changes (between the
anticodon-binding and tRNA synthetase domains). The
contacts were calculated with the PRODIGY web server
(Xue et al., 2016). The specific interactions were calculated
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with Protein Interactions Calculator web server (Tina et
al., 2007). The impact of novel p.T1068M and previously
reported p.R1058Q, p.M1064I, p.F1072L mutations on
the anticodon-binding domain’s stability were calculated
with the MAESTROWeb (Laimer et al., 2015). We also
used mutfunc web-server to check whether the mutations
would lead to loss-of-function (http://www.mutfunc.com).
3. Results
3.1. Affected individual
A 45-day-old infant presented with migrating myoclonic
seizures that had been lasting for three days. The seizures
were apparent both during sleep and activity. She had focal
tonic and clonic seizures. The infant was delivered to a
39-year-old mother with gestational diabetes without any
complication at the 38th week of gestation via caesarean
section. Upon her birth, she was weighing 3300 g. She was
the third child of healthy parents who were first cousins.
Before having her, the parents had two healthy daughters.
The affected individual’s past medical history included
two hospitalizations. She was hospitalized the first time
when she was three days old due to dehydration and
hypernatremia. She was then hospitalized when she was
15 days old due to urinary tract infection with indications
of microcephaly, left renal agenesis, and patent foramen
ovale. Her physical examination demonstrated that she
had microcephaly, bifrontal narrowing, and high palate.
She had mild axial hypotonia with slightly increased
deep tendon reflexes, bilateral clonus without Babinski
sign. She also had mild upper limb spasticity. Her ocular
and hearing examinations were normal. Her laboratory
examinations were normal with regard to complete blood
count, and biochemistry tests (i.e. blood glucose, creatine
kinase, lactate, ammonia, hepatic and renal function tests,
lipid profile, vitamin B12, thyroid hormones, metabolic
screening including urine organic acids, very long chain
fatty acids, acylcarnitines, plasma and urine amino
acids, lysosomal enzymes, serum lactate and pyruvate,
biotinidase activity, cerebrospinal fluid (CSF) amino acid
analysis, CSF/serum glycine and glucose ratios, urine
sulfite screening). The electroencephalography showed
multifocal epileptic activity. The brain magnetic resonance
(MR) imaging revealed diffuse T2 hyperintensity in
cerebral white matter. The MR spectroscopy indicated
minimally increased lactate peak. Skeletal X-ray was
normal. Her follow-up examinations at three months
of age revealed that her clinical presentation progressed
leading to axial hypotonia with increased deep tendon
reflexes, clonus, and spasticity. She had severe global
developmental delay without head control, eye contact, or
tracking too. She had epileptic encephalopathy with drug
(clobazam, clonazepam, levetiracetam, phenobarbital,
potassium bromide, pyridoxine, topiramate, and ketogenic
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diet) resistant seizures. She died at the age of 11 months due
to complications caused by an upper respiratory infection.
3.2. The whole exome sequencing identifies a homozygous
missense VARS1 variant
The WES analysis of the affected individual’s proband
revealed eight homozygous variants (Supplementary Table
1). Among these, only the variants observed in VARS1,
LAMC2, and USP24 genes occurred at conserved positions
(for VARS1, please see Supplementary Figure 2A). The
fact that the previously reported VARS1 mutations were
associated with microcephaly and epilepsy made us
focus on the VARS1 variant. The VARS1 gene variant is
located at the 31747470th nucleotide of chromosome 6
(6:31747470 (GRCh37), NC_000006.11:g.31747470G>A),
leading to a p.Thr1068Met (p.T1068M, rsID: rs777665186)
substitution (Figure 1A). This variant has previously been
observed with 0.00002 worldwide frequency, but it has
never been linked to a clinical condition. It was determined
to be homozygous in the proband and heterozygous in
other family members (see Section 2). Sanger sequencing
confirmed proband’s homozygous c.3203G>A variation
(Figure 1A). To further validate the genotype of the
family concerning the identified mutation, VARS1 gene
around the mutation site was PCR amplified and subjected
to Tsp45I digestion. The c.3203G>A site prevents the
proband’s DNA cleavage by Tsp45I, as it coincides with
the restriction site of the enzyme (Figure 1B). On the
other hand, the parents’ and one unaffected sister’s
DNA indicated a pattern compatible with heterozygous
mutation, while the other sister contained two healthy
alleles (Figures 1C and 1D). Considering the clinical
outcome of the previously reported VARS1 variants (MIM:
617802, phenotype: neurodevelopmental disorder with
microcephaly, seizures, and cortical atrophy), together
with the condition of our affected individual suggested
further exploration of the autosomal recessive p.T1068M
VARS1 mutation.
3.3. Anticodon-binding domain of VARS1 is a mutational
hotspot
VARS1 is composed of glutathione S-transferase
C-terminal, tRNA synthetase class 1, anticodon-binding
and coiled coil domains (Supplementary Figure 1B). So
far, including the one we report here, 19 VARS1 mutations
have been described (Figure 2A). Interestingly, 17 of these
mutations occurred as homozygous or heterozygous
missense mutations, mostly localized on the tRNA
synthetase and anticodon-binding domains. A 15 amino
acid long stretch of the anticodon-binding domain
(encoded by the exon 27 of 207 bp length) harbors our
described p.T1068M mutation, as well as the previously
reported pathogenic p.R1058Q (recurrent), p.M1064I, and
p.F1072L mutations. To observe the spatial distribution of
these mutations, we modeled human VARS1 in complex
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Figure 1. Sanger validation and segregation analysis of VARS1 variant identified
in. A: Sanger sequencing of the blood DNA from the proband confirmed
homozygous c.3203G>A mutation identified by WES. B: The c.3203G>A mutation
occurred in a recognition and cutting site by Tsp45I restriction enzyme. C: The
proband (black circled), her parents (2 and 3) and her two unaffected siblings (4 and
5) studied during the segregation analysis by using Tsp45I digestion. D: Agarose
electrophoresis demonstrating homozygous mutation in the proband (MT 488bp),
heterozygous mutations in parents and one sister (WT 257/231, MT 488 bp), and
wild-type status (WT 257/231) in the other sister.

with its tRNA, by using the valyl-tRNA Synthetase (ValRS)
from Thermus thermophilus as a template (see Section 2;
Supplementary Figure 1B). As a result, we found out that
p.R1058Q, p.M1064I, p.T1068M, p.F1072L mutations are
clustered within a helix-turn-helix (HTH) motif, running
between Q1047-L1075 (Figures 2B and 2C). This HTH
motif is located across the anticodon-binding and tRNA
synthetase domain interface (Supplementary Figure
1B, Figure 2B). We also explicitly modeled p.R1058Q,
p.M1064I, p.T1068M, p.F1072L VARS1 point mutations
(see Section 2). The structural analysis of the mutant VARS1

structures revealed that each of these four mutations has
the potential to reduce the number of (anticodon-binding
and tRNA synthetase) domain-domain contacts by 10%
(see Section 2; Supplementary Table 2). This reduction
is triggered by the loss of interhelical hydrophobic (for
p.M1064I and p.F1072M) and electrostatics interactions
(for p.R1058Q and p.T1068M). Specifically, in the case of
p.T1068M, residue 1068 is unable to make a stabilizing
hydrogen bond with p.S1061 located on a reciprocal helix
(Figure 2D). These observations were further supported
by the MAESTROWeb and mutfunc web-servers, which
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predicted all of these mutations to be destabilizing/
deleterious (Supplementary Table 3, Supplementary Figure
2B).
4. Discussion
Karaca et al. (2015) was the first group reporting two
homozygous, VARS1 gene variants (p.R1058Q and
p.L885F, respectively) in two families of consanguineous
couples. Three children coming from these families
experienced microcephaly, intellectual disability, seizures,
and cortical atrophy. Alsemari et al. (2017a, 2017b) then
described a homozygous p.R1217H VARS1 mutation
in a boy with severe mental retardation, ataxia, speech
impairment, epilepsy, short stature, microcephaly,
hypogonadism, and growth hormone deficiency. Stephen
et al. (2018) also reported two siblings with severe early-

onset neurological manifestations including microcephaly,
intellectual disability, seizures, and cortical atrophy. The
affected individuals demonstrated some dysmorphic
facial features. WES analysis of these affected individuals
detected two mutations in VARS1: a missense p.M1064I
mutation in one allele and a splice site mutation resulting in
a truncation in the other allele. Okur et al. (2018) reported
two male siblings aged 15- and 10-year-old who had an
intellectual deficiency, developmental delay, severe speech
impairment, microcephaly, and prematurity. Both affected
individuals were compound heterozygous with p.A22D and
p.F1072L mutation in VARS1 gene. Recently, two further
studies were published reporting new VARS1 variants.
Siekierska et al. (2019) described ten affected individuals
from seven families with biallelic variants in VARS1. All
affected individuals demonstrated global developmental

Figure 2. Structural mapping of the pathogenic VARS1 mutation cluster. A: Domain organization of VARS1 (yellow: glutathione
S-transferase, orange: tRNA synthetase, blue: anticodon-binding, green: coiled coil) together with the localization of the reported
pathogenic mutations. Light blue and gray boxes correspond to the low complexity regions, as annotated by Pfam (El-Gebali et al.,
2019). The novel p.T1068M mutation is depicted in salmon. B: The structural model of VARS1 anticodon-binding domain harboring
pathogenic mutations. The color coding follows the one given in panel A. C: The structural motif belonging to the wild type anticodonbinding domain (running between amino acids Q1047 and P1090) is located in the middle. The wild type motif is surrounded by the
close-up of each observed mutation position. In each oval, the conformation of the mutant amino acid (gray) is compared to its wild
type counterpart. D: In the wild type VARS1, S1061 is making a stabilizing interhelical polar contact with T1068 (depicted by Pymol
(Schrödinger LLC, 2015)). This interaction is lost in the case of p.T1068M substitution.
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delay, microcephaly, and intellectual disability. Eight out of
ten affected individuals had epileptic seizures and cerebral
atrophy. Friedman et al. (2019) reported seven affected
individuals from five unrelated families with five different
biallelic missense VARS1 variants. Subjects presented with
global developmental delay, epileptic encephalopathy,
primary or progressive microcephaly, and cortical
atrophy. While the mutations reported by Siekierska et al.
(2019), Friedman et al. (2019), and Stephen et al. (2018)
are heterozygous together with a missense mutation, all
other known mutations of VARS1 are biallelic missense
mutations (Figure 2A). The lack of affected individuals with
a total loss of intact protein strongly suggests that VARS1
is a vital protein. Thus, missense variants of VARS1 are
probably sufficient to maintain the vital functions, except
for the normal development and/or function of the brain
tissue. Our affected individual presenting the homozygous
p.T1068M VARS1 mutation has some common features
with the abovedescribed affected individuals, including
microcephaly, developmental delay, and intractable
seizures. Though, she did not have cortical atrophy. In the
reports of Okur et al. (2018) and Siekierska et al. (2019),
some of the affected individuals did not demonstrate
cortical atrophy too. This indicates that cortical atrophy is
either not a persistent outcome of VARS1 mutations or is
acquired with time.
When compared with the affected individuals presented
in the literature, it can be claimed that the neurological
signs and symptoms of our case were more severe. She
had axial hypotonia without head control and pyramidal
symptoms including increased deep tendon reflexes with
bilateral clonus and upper limb spasticity. She had no eye
contact, and her microcephaly was prominent. She also
had epileptic encephalopathy with refractory myoclonic
seizures. Despite the use of many antiseizure drugs and
ketogenic diet, her seizures continued. Her death due to
an intervening respiratory infection was probably due to
problems associated with severe neuromotor retardation
and refractory epileptic encephalopathy. Affected
individuals living up to 10 years of age have been reported
in the literature, but our case died before reaching the
age of one. Therefore, we cannot comment on whether
symptoms such as cortical atrophy described in older
children in the literature will also develop in our patient.
One distinctive clinical feature of our affected individual
was her left renal agenesis. This finding was not described
in any of the affected individual with VARS1 mutation
reported in the literature. Since parents of the case were
consanguineous as first cousins, the finding of left renal
agenesis may be associated with a genetic defect other than
VARS1. However, we think that it is important to consider
this finding in our case and to report it to the literature. The
interpretation of whether this finding is related to VARS1

mutation or an incidental finding can be made when more
VARS1 related affected individuals are reported in the
literature.
To further explore the impact of the detected
mutation, we structurally modeled human VARS1 and
interpreted p.T1068M within the spatial distribution
of previously reported VARS1 variants. As a result, we
uncovered that p.T1068M is clustered with three other
pathogenic mutations (p.R1058Q, p.M1064I, p.T1068M,
and p.F1072L) in a 15 amino acid long stretch of the
anticodon-binding domain. Further, we showed that all
these four mutations lead to the reduction in the number
of anticodon-binding and catalytic tRNA synthetase
domain-domain interactions by using computational
approaches. We supply our models together with this
paper as supplementary material to aid the drug design
approaches targeting these VARS1 mutations.
5. Conclusion
In this work, we screened a small set of consanguineous
Turkish families with children suffering from different
diseases, mostly neurological disorders by using whole
exome sequencing. This study allowed us to identify a
novel VARS1 variant leading to a p.T1068M mutation.
This mutation is located very close to previously reported
pathogenic p.R1058Q. Here, we show that a helixturn-helix motif on the anticodon-binding domain of
VARS1 not only harbors p.T1068M, but also three other
pathogenic VARS1 mutations. We demonstrate that all
these mutations are potentially capable of destabilizing
anticodon-binding and catalytic tRNA synthetase
domain-domain interactions. It is highly likely that such
destabilization hinders the optimal enzymatic activity of
VARS1 without compromising vital function. We expect
that this realization will pave the way for the development
of drugs, capable of enhancing mutant VARS1 stability.
Conflict of interest
All authors declare lack of conflict of interest in relation to
this report.
Data availability
The atomic coordinates of our models and original gel
images are provided as Supporting Information.
Acknowledgments
We thank all participating patient families to this study.
This project was supported by the Department of Scientific
Research Projects of Dokuz Eylül University as numbered
as 2014.KB.SAG.054 and İzmir Biomedicine and Genome
Center.

463

HIZ et al. / Turk J Biol
References
Alsemari A, Al-Younes B, Goljan E, Jaroudi D, BinHumaid F et al.
(2017a). Correction to: Recessive VARS2 mutation underlies
a novel syndrome with epilepsy, mental retardation, short
stature, growth hormone deficiency, and hypogonadism.
Human Genomics 11 (1): 33. https://doi.org/10.1186/s40246017-0130-6
Alsemari A, Al-Younes B, Goljan E, Jaroudi D, BinHumaid F et
al. (2017b). Recessive VARS2 mutation underlies a novel
syndrome with epilepsy, mental retardation, short stature,
growth hormone deficiency, and hypogonadism. Human
Genomics 11 (1): 28. https://doi.org/10.1186/s40246-0170124-4
Alva V, Nam SZ, Soding J, Lupas AN (2016). The MPI bioinformatics
Toolkit as an integrative platform for advanced protein
sequence and structure analysis. Nucleic Acids Research 44
(W1): W410-415. https://doi.org/10.1093/nar/gkw348
Antonellis A, Green ED (2008). The role of aminoacyl-tRNA
synthetases in genetic diseases. Annual Review of Genomics
and Human Genetics 9: 87-107. https://doi.org/10.1146/
annurev.genom.9.081307.164204
Auton A, Abecasis GR, Altshuler DM, Durbin RM, Abecasis
GR et al. (2015). A Global Reference for Human Genetic
Variation. Nature 526 (7571): 68–74. https://doi.org/10.1038/
nature15393.
Cingolani P, Platts A, Wang le L, Coon M, Nguyen T et al. (2012).
A program for annotating and predicting the effects of single
nucleotide polymorphisms, SnpEff: SNPs in the genome
of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly
(Austin) 6 (2): 80-92. https://doi.org/10.4161/fly.19695
DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR et al.
(2011). A framework for variation discovery and genotyping
using next-generation DNA sequencing data. Nature Genetics
43 (5): 491-498. https://doi.org/10.1038/ng.806
El-Gebali S, Mistry J, Bateman A, Eddy SR, Luciani A et al. (2019).
The Pfam protein families database in 2019. Nucleic Acids
Research 47 (D1): D427-D432. https://doi.org/10.1093/nar/
gky995
Friedman J, Smith DE, Issa MY, Stanley V, Wang R et al. (2019).
Biallelic mutations in valyl-tRNA synthetase gene VARS are
associated with a progressive neurodevelopmental epileptic
encephalopathy. Nature Communications 10 (1): 707. https://
doi.org/10.1038/s41467-018-07067-3
Fukai S, Nureki O, Sekine S, Shimada A, Vassylyev DG et al.
(2003). Mechanism of molecular interactions for tRNA (Val)
recognition by valyl-tRNA synthetase. RNA 9 (1): 100-111.
https://doi.org/ 10.1261/rna.2760703
Karaca E, Harel T, Pehlivan D, Jhangiani SN, Gambin T et al.
(2015). Genes that Affect Brain Structure and Function
Identified by Rare Variant Analyses of Mendelian Neurologic
Disease Neuron 88 (3): 499-513. https://doi.org/10.1016/j.
neuron.2015.09.048

464

Laimer J, Hofer H, Fritz M, Wegenkittl S, Lackner P (2015).
MAESTRO--multi agent stability prediction upon point
mutations. BMC Bioinformatics 16: 116. https://doi.
org/10.1186/s12859-015-0548-6
Li H, Durbin R (2010). Fast and accurate long-read alignment with
Burrows-Wheeler transform. Bioinformatics 26 (5): 589-595.
https://doi.org/10.1093/bioinformatics/btp698
Meyer-Schuman R, Antonellis A (2017). Emerging mechanisms
of aminoacyl-tRNA synthetase mutations in recessive and
dominant human disease. Human Molecular Genetics 26 (R2):
R114-R127. https://doi.org/10.1093/hmg/ddx231
Okur V, Ganapathi M, Wilson A, Chung WK (2018). Biallelic
variants in VARS in a family with two siblings with intellectual
disability and microcephaly: case report and review of the
literature. Cold Spring Harbor Molecular Case Studies 4 (5).
https://doi.org/10.1101/mcs.a003301
Schimmel P (2018). The emerging complexity of the tRNA world:
mammalian tRNAs beyond protein synthesis. Nature Reviews
Molecular Cell Biology 19 (1): 45-58. https://doi.org/10.1038/
nrm.2017.77
Schrödinger LLC (2015). The PyMOL Molecular Graphics System,
Version 1.8.6.2 Schrödinger, LLC.
Siekierska A, Stamberger H, Deconinck T, Oprescu SN, Partoens
M et al. (2019). Biallelic VARS variants cause developmental
encephalopathy with microcephaly that is recapitulated in
vars knockout zebrafish. Nature Communications 10 (1): 708.
https://doi.org/10.1038/s41467-018-07953-w
Stephen J, Nampoothiri S, Banerjee A, Tolman NJ, Penninger JM
et al. (2018). Loss of function mutations in VARS encoding
cytoplasmic valyl-tRNA synthetase cause microcephaly,
seizures, and progressive cerebral atrophy. Human Genetics
137 (4): 293-303. https://doi.org/10.1007/s00439-018-1882-3
Tina KG, Bhadra R, Srinivasan N (2007). PIC: Protein Interactions
Calculator. Nucleic Acids Research 35 (2): W473-476. https://
doi.org/10.1093/nar/gkm423
Van Zundert GCP, Rodrigues J, Trellet M, Schmitz C, Kastritis PL
et al. (2016). The HADDOCK2.2 Web Server: User-Friendly
Integrative Modeling of Biomolecular Complexes. Journal of
Molecular Biology 428 (4): 720-725. https://doi.org/10.1016/j.
jmb.2015.09.014
Webb B, Sali A (2014). Protein structure modeling with MODELLER.
Methods in Molecular Biology 1137: 1-15. https://doi.
org/10.1007/978-1-4939-0366-5_1
Xue LC, Rodrigues JP, Kastritis PL, Bonvin AM, Vangone A (2016).
PRODIGY: a web server for predicting the binding affinity of
protein-protein complexes. Bioinformatics 32 (23): 3676-3678.
https://doi.org/10.1093/bioinformatics/btw514

HIZ et al. / Turk J Biol

Supporting Information

VARS1 Mutations Associated with Neurodevelopmental Disorder Are Located on A Short Amino Acid Stretch of
The Anticodon-Binding Domain
Semra HIZ1,2,3, Seval KILIÇ1,3, Güney BADEMCİ4, Tülay KARAKULAK1,3, Aybike ERDOĞAN1,3,
Burcu ÖZDEN1,3, Çiğdem ERESEN5, Esra ERDAL1,3,5, Uluç YİŞ2, Mustafa TEKİN4,
Gökhan KARAKÜLAH1,3,**, Ezgi KARACA1,3,*, **, Mehmet ÖZTÜRK1,3
1İzmir Biomedicine and Genome Center, İzmir, Turkey
2Department of Pediatrics, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey
3Dokuz Eylül University, İzmir International Biomedicine and Genome Institute, İzmir, Turkey
4John P. Hussman Institute for Human Genomics and Dr. John T. Macdonald Foundation Department of Human
Genetics, University of Miami Miller School of Medicine, Miami, USA
5Department of Medical Biology and Genetics, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey
*Equally Contributing Corresponding Authors: ezgi.karaca@ibg.edu.tr; gokhan.karakulah@ibg.edu.tr

1

HIZ et al. / Turk J Biol
Supporting Figures

Supplementary Figure 1. (A) AlphaFold2 model (white) is aligned with Thermus thermophilus valyl-tRNA Synthetase (pdb id: 1IVS,
yellow) as the best structural template to homology model VARS1. (B) The structural model of the human VARS1 (all depicted in
cartoon). The domain coloring follows the scheme reported in Figure 2. tRNA is colored in gray.
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Supplementary Figure 2. A. T1068 is conserved across different organisms. B. Mutfunc webserver (http://www.mutfunc.com)
predicts the amino acids substitutions occurring in the mutation cluster to be impactful due to the conserved positions of these
substitutions.
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Supplementary Table 1. The list of homozygous variants identified in the proband.

Chromosome Chr Start

Chr End

Var. Ref Var
rsid List
Type Seq Seq

Genes
List

1

53108597

53108597

SNP
C
(X2)

G

1

183189995 183189995

SNP
A
(x2)

C

LAMC2

4

68384019

68384019

SNP
C
(x2)

A

CENPC

6

31747470

31747470

SNP
G
(x2)

A

12

95927026

95927026

SNP
T
(x2)

A

12

101777396 101777396

SNP
A
(x2)

12

104054522 104054522

12

108961059 108961059

Gene
Prot
aa
Component
Impact List Change
List

rs200885042 FAM159A CDS

MISSENSE A-82-G

0.01

no

CDS

MISSENSE N-180-T

0

Yes (5.4)

CDS

MISSENSE D-229-y

0

no

CDS

MISSENSE T-1068-M 0.01

Yes (5 .3)

USP44

CDS

MISSENSE E-336-V

Yes (4.9)

G

rs139767850 UTP20

CDS

MISSENSE M-2669-V 0.02

no

SNP
A
(x2)

T

STAB2

CDS

MISSENSE Q-617-L

0

no

SNP
T
(x2)

G

ISCU

INTBQN;
CDS

MISSENSE S-14 5-A

0

no

rs777665186 VARS

Supplementary Table 2: Number of contacts calculated by PRODIGY
between the anticodon-binding and tRNA synthetase domains, in the case
of mutant and wild-type VARS1 (Xue et al., 2016).
Contact types

WT p.R1058Q p.M1064I p.T1068M p.F1072L

charged-charged: 4

3

4

3

3

charged-polar:

12

12

12

12

13

charged-apolar:

48

46

47

47

44

polar-polar:

2

2

2

2

2

polar-apolar:

28

29

23

29

24

apolar-apolar:

75

73

Total

170 165

70

74

78

158

167

163

Supplementary Table 3: Stability Predictions
calculated by the MaestroWeb web-server
for the anticodon-binding domain mutations
(Laimer et al., 2015).
Mutation

MaestroWeb (arbitrary units)

p.T1068M 0.49 (Destabilizing)
p.R1058Q 1.83 (Destabilizing)

4

Global
Mammalian
Allele
Conservation
Freq.

p.M1064I

0.84 (Destabilizing)

p.F1072L

1.76 (Destabilizing)

0
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Appendix

Figure 1D – original gel images:
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